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Abstract
Background:  Epithelial to Mesenchymal Transition (EMT) induced by Transforming Growth
Factor-β (TGF-β) is an important cellular event in organogenesis, cancer, and organ fibrosis. The
process to reverse EMT is not well established. Our purpose is to define signaling pathways and
transcription factors that maintain the TGF-β-induced mesenchymal state.
Results: Inhibitors of five kinases implicated in EMT, TGF-β Type I receptor kinase (TβRI), p38
mitogen-activated protein kinase (p38 MAPK), MAP kinase kinase/extracellular signal-regulated
kinase activator kinase (MEK1), c-Jun NH-terminal kinase (JNK), and Rho kinase (ROCK), were
evaluated for reversal of the mesenchymal state induced in renal tubular epithelial cells. Single
agents did not fully reverse EMT as determined by cellular morphology and gene expression.
However, exposure to the TβRI inhibitor SB431542, combined with the ROCK inhibitor Y27632,
eliminated detectable actin stress fibers and mesenchymal gene expression while restoring
epithelial E-cadherin and Kidney-specific cadherin (Ksp-cadherin) expression. A second
combination, the TβRI inhibitor SB431542 together with the p38 MAPK inhibitor SB203580, was
partially effective in reversing EMT. Furthermore, JNK inhibitor SP600125 inhibits the effectiveness
of the TβRI inhibitor SB431542 to reverse EMT. To explore the molecular basis underlying EMT
reversal, we also targeted the transcriptional repressors ZEB1 and ZEB2/SIP1. Decreasing ZEB1
and ZEB2 expression in mouse mammary gland cells with shRNAs was sufficient to up-regulate
expression of epithelial proteins such as E-cadherin and to re-establish epithelial features.
However, complete restoration of cortical F-actin required incubation with the ROCK inhibitor
Y27632 in combination with ZEB1/2 knockdown.
Conclusions:  We demonstrate that reversal of EMT requires re-establishing both epithelial
transcription and structural components by sustained and independent signaling through TβRI and
ROCK. These findings indicate that combination small molecule therapy targeting multiple kinases
may be necessary to reverse disease conditions.
Published: 21 December 2009
BMC Cell Biology 2009, 10:94 doi:10.1186/1471-2121-10-94
Received: 9 June 2009
Accepted: 21 December 2009
This article is available from: http://www.biomedcentral.com/1471-2121/10/94
© 2009 Das et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
Page 2 of 18
(page number not for citation purposes)
Background
Epithelial to Mesenchymal Transition (EMT) is an
extreme form of cellular plasticity defined by loss of epi-
thelial cell morphology, dissociation of cell-cell contacts,
reduction in proteins mediating cell-cell contacts, remod-
eling of the actin cytoskeleton, de novo expression of α-
smooth muscle actin (α-SMA), and acquisition of mesen-
chymal cell shape [1-4]. During EMT, cells diminish epi-
thelial gene expression and acquire mesenchymal gene
expression [5]. Cortical actins, the actin filament bundles
below the plasma membrane, reorganize or are lost, while
stress fibers comprising F-actin are gained. In normal
development, EMT has been associated with processes in
gastrulation, heart formation, palate formation, and Mul-
lerian tract regression [4]. In disease states, EMT has been
exploited in both cancer and organ fibrosis. The mortality
in human cancers is caused by primary tumor cells that
have undergone oncogenic EMT and metastasized to
other organs. Other diseases, such as end-state organ fail-
ure by fibrosis, are caused by repeated and sustained
infliction of EMT. Thus, understanding the cellular mech-
anisms to reverse EMT is of great importance.
The TGF-β signaling pathway is considered a good target
for EMT reversal because it is a key mediator of fibrosis
and facilitator of metastasis [3,6]. TGF-β induces EMT by
both Smad-dependent and -independent signaling events
[4,7,8]. TGF-β1 ligand exerts its signaling effects by acti-
vating a heteromeric receptor of two transmembrane ser-
ine/threonine kinases, type I and type II receptors (TβRI
and TβRII) [7,9]. TβRII transphosphorylates TβRI, activat-
ing its kinase function. Activated TβRI then phosphor-
ylates the intracellular proteins Smad2 and Smad3. The
phosphorylated Smad2 and Smad3 associate with Smad4,
with the activated complex translocating to the nucleus
where it interacts with other transcriptional co-activators
and co-repressors to regulate expression of numerous
genes [10]. This Smad-dependent signaling up-regulates
expression of several transcription factors important for
EMT induction, including Snail, Slug, Twist, and members
of the ZFH family, ZEB1 (also called EF1, TCF8, AREB6,
ZFHEP, NIL-2A, ZFHX1A, and BZP) and ZEB2 (also called
SIP1, SMADIP1, ZFHX1B, and KIAA0569) [11-13].
Of particular importance are ZEB1 and ZEB2 because they
are crucial regulators of EMT during embryonic develop-
ment and cancer [14,15]. These transcription factors acti-
vate EMT by binding to E-box elements present in the E-
cadherin promoter, suppressing synthesis of this cell-cell
adhesion protein [16,17]. ZEB1 also promotes EMT by
repressing expression of basement membrane compo-
nents and cell polarity proteins [13,14,18,19]. ZEB2 has
also been implicated in the induction of EMT [13]. The
loss of E-cadherin and other epithelial structural compo-
nents is a major event during EMT. Mutations in the TCF8
gene (GenBank accession number NM 030751) result in a
mesenchymal to epithelial transition (MET) in mouse
embryos by reprogramming gene expression, leading to
developmental defects by diminishing progenitor cell
proliferation and cell migration [20]. Thus, it is crucial to
understand the role of ZEB1 and ZEB2 in the reversal of
TGF-β-induced EMT.
Multiple signaling proteins in addition to Smads have
been implicated in the induction of EMT by TGF-β1.
These include Ras/MAPK [21], integrin β-1[22], integrin-
linked kinase [23], p38 mitogen-activated protein kinase
(p38 MAPK) [24], RhoA Kinase (ROCK) [25], phosphati-
dylinositol 3-OH kinase (PI3K) [26], Jagged1/Notch [27],
SARA [28], nuclear factor kappa-B (NF-B) [29], Par6
[8,30], and ERK [31]. However, much less is known about
how these signaling pathways and transcription factors
maintain the mesenchymal program. Studies examining
the reversal of EMT by perturbing one component of a sig-
naling pathway with inhibitors or shRNAs demonstrate
partial reversal of the mesenchymal state [32,33].
Here, we report full reversal of EMT morphology and pat-
terns of gene expression by concurrently inhibiting TβRI
kinase and ROCK. We show that inhibition of TβRI kinase
blocks mesenchymal gene expression, an effect mediated
by down-regulation of ZEB1 and ZEB2 levels, while the
ROCK inhibitor stabilizes the epithelial structure. These
findings demonstrate that combined use of TβRI kinase
and ROCK inhibitors is important to decrease TGF-β sign-
aling to enable full reversal of EMT.
Results
TGF-β1 induces EMT in mTEC-KO cells
We used primary mouse tubular epithelial cells isolated
from the renal cortex of TGF-β1 knockout mice (mTEC-
KO cells) to model EMT in culture [34]. The mTEC-KO
cells exhibit greater epithelial features than do wild-type
renal epithelial cells. Renal tubular epithelial cells were
chosen because of the correlation between the extent of
tubulointerstitial fibrosis and the prognosis for end-stage
renal disease [35]. In the absence of TGF-β1, mTEC-KO
cells form an epithelial sheet; incubation with 100 pM
TGF-β1 for 72 hours induced the mTEC-KO cells to
acquire a more fibroblast-like, spindle shaped morphol-
ogy indicative of mesenchymal cells (Figure 1A). Incuba-
tion with the TβRI inhibitor SB431542 blocked the TGF-
β1-induced transition of the mTEC-KO epithelial cells
into mesenchymal cells. The morphological transforma-
tion correlated with major changes in the actin cytoskele-
ton as revealed by phalloidin staining. Untreated
epithelial cells exhibited a cortical actin staining below
the cell membranes, whereas the TGF-β1-treated cells dis-
played elongated F-actin stress fibers. In the cells treatedBMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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TGF-β1 induces EMT in renal tubular epithelial cells Figure 1
TGF-β1 induces EMT in renal tubular epithelial cells. (A) Phase contrast (left) and Phalloidin staining (right) of mTEC-
KO cells incubated for 72 hours as indicated without TGF-β1, with 100 pM TGF-β1, or with TGF-β1 and 10 μM SB431542. 
Cell morphology was observed by bright field phase microscopy at 100× magnification. Phalloidin was used to detect F-actin at 
400× magnification, while DAPI was used to detect nuclei. White arrows point to stress fibers. (B) Immunoblot showing pro-
tein expression of E-cadherin, α-SMA, and β-tubulin following incubation of mTEC-KO cells with 100 pM TGF-β1 for the indi-
cated times. A dash indicates non-detectable levels of protein, while a plus sign indicates detectable protein levels over 
background. (C-E) show quantitative RT-PCR analysis of (C) Ksp-cadherin, (D) MMP-9, and (E) SM22 RNA levels in mTEC-
KO cells incubated with TGF-β1 for the indicated times. Asterisks (*) indicate significant differences (P < 0.05, n = 9).BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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with the TβRI inhibitor SB431542, short, non-cortical
actin fibers were detected.
The structural integrity and polarization of epithelial cells
is maintained by E-cadherins binding to catenins and a
network of actin filaments; reduction of E-cadherin
expression is a hallmark of mesenchymal acquisition [36].
Thus, we also examined the expression levels of several
genes regulated by TGF-β1 as markers for the epithelial
and mesenchymal states. In mTEC-KO cells, incubation
with TGF-β1 led to a significant decrease in expression of
the epithelial protein E-cadherin and increase in expres-
sion of the mesenchymal protein α-smooth muscle actin
(α-SMA) by 72 hours (Figure 1B).
Because TGF-β1 is known to regulate expression of multi-
ple cadherins, we also examined expression of Kidney-
specific cadherin (Ksp-cadherin). Ksp-cadherin has a sim-
ilar developmental pattern of expression as the tight junc-
tion proteins ZO-1 and claudin-3 in kidney epithelial
cells; therefore, it is used as a marker of the epithelial state
[37,38]. Incubation with TGF-β1 led to a significant
reduction in the level of Ksp-cadherin RNA (Figure 1C),
while it led to significant increases in the RNA levels of
mesenchymal markers matrix metalloproteinase-9 (MMP-
9) (Figure 1D) and smooth muscle protein 22 (transgelin)
(SM22) (Figure 1E). MMP-9 is an important extracellular
matrix-degrading enzyme; SM22 has been shown to drive
smooth muscle-specific gene expression in vivo [39-41].
Thus, we conclude that mTEC-KO cells completed the
EMT program by several criterions following incubation
with TGF-β1.
A combination of TβRI inhibitor with either ROCK or p38 
MAPK inhibitors is required for complete EMT reversal
To examine the reversibility of EMT induced by TGF-β1 in
mTEC-KO cells, we looked at the effects of five different
kinase inhibitors targeting TβRI, p38 mitogen-activated
protein kinase (p38 MAPK), MAP kinase kinase/extracel-
lular signal-regulated kinase activator kinase (MEK1), c-
Jun NH-terminal kinase (JNK), and Rho kinase (ROCK)
with SB431542, SB203580, U0126, SP600125, and
Y27632, respectively. These kinase inhibitors were previ-
ously implicated in EMT [24,31,42-44], 42-44 and their
specificities have been well studied [45,46]. The cells were
first incubated with 100 pM TGF-β1 for 72 hours to
induce EMT, the kinase inhibitors were then added, and
incubation was continued for an additional 24 hours.
Addition of TβRI inhibitor SB431542 at 5 μM for 24 hours
was sufficient to reduce significantly the RNA level of the
TGF-β-responsive gene plasminogen activator inhibitor-1
(PAI-1) [47], demonstrating that TGF-β1 signaling was
effectively inhibited (Figure 2).
To assess the effects of the kinase inhibitors on EMT, the
actin cytoskeleton was examined by phalloidin staining.
In contrast to its ability to prevent induction of EMT by
TGF-β1 (Figure 1) and to reverse the elevation of PAI-1
expression (Figure 2), the TβRI inhibitor SB431542 failed
to reverse the mesenchymal actin stress fiber morphology
of the TGF-β1-treated mTEC-KO cells (Figure 3C). Inhibi-
tion of other kinases previously implicated in inducing
EMT, such as p38 MAPK, MEK1, JNK, and ROCK, also did
not reverse the actin stress fiber morphology induced in
the mTEC-KO cells by TGF-β1 (Figures 3D-G). These
results indicate that individual kinase inhibitors cannot
fully reverse TGF-β1-induced EMT in mTEC-KO cells.
Since EMT effects are mediated by multiple cellular path-
ways, we also tested pair wise combinations of inhibitors
of TβRI (5 μM SB431542), p38 MAPK (1 μM SB203580),
ROCK (1 μM Y27632), MEK1 (10 μM U0126), and JNK
(15 μM SP600125) (Figures 3H-K). We chose to use low
doses of the inhibitors to reduce the chance of non-spe-
cific small molecule binding [45,48]. When the TβRI
inhibitor SB431542 was combined with either p38 MAPK
inhibitor SB203580 or ROCK inhibitor Y27632 for 24
hours, the epithelial appearance was restored (Figures 3H
and 3I). The TβRI inhibitor SB431542 plus p38 MAPK
inhibitor SB203580 (Figure 3H) reduced the presence of
stress fibers more than either treatment by itself. However,
non-cortical actin filaments were still detectable. Detecta-
ble actin stress fibers were eliminated by the combination
of TβRI inhibitor SB431542 and ROCK inhibitor Y27632
(Figure 3I). Cortical actin bordering the cell-cell junctions
was restored by both combinations. The addition of either
MEK1 inhibitor U0126 or JNK inhibitor SP600125 along
with TβRI inhibitor SB431542 had no detectable effect on
the mesenchymal phenotype of the cells (Figures 3J and
3K). The combination of p38 MAPK inhibitor SB203580
and ROCK inhibitor Y27632 restored cortical actin stain-
ing, but stress fiber actin remained in the cells (Figure 3L).
Increasing the concentration of TβRI inhibitor SB431542
to 10 μM led to a further decrease in the level of stress fib-
ers; however, the combination of TβRI inhibitor
SB431542 with a p38 MAPK inhibitor SB203580 or
ROCK inhibitor Y27632 was more effective at eliminating
them (Additional File 1). Similar results were observed in
wild-type mTEC cells, with a combination of TβRI inhibi-
tor SB431542 and ROCK inhibitor Y27632 reversing EMT
as indicated by both gene expression (data not shown)
and cell morphology (Additional File 2). Collectively,
these data indicate that treatment of the cells with TβRI
inhibitor SB431542 by itself cannot lead to full re-acqui-
sition of cortical actin at the cell junctions.
The effects of individual or combinations of kinase inhib-
itors on the expression of several genes altered by EMT
were also examined by quantitative RT-PCR. The mTEC-BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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KO cells were treated with 100 pM TGF-β1 to transition
into the mesenchymal state; afterward, the kinase inhibi-
tors were added. Incubation with TGF-β1 significantly
reduced the Ksp-cadherin RNA level within 24 hours (Fig-
ures 1 and 4A). Addition of either TβRI inhibitor
SB431542 or ROCK inhibitor Y27632 to the mesenchy-
mal cells did not restore Ksp-cadherin RNA to pre-TGF-β1-
levels (Figure 4A). Incubation with p38 MAPK inhibitor
SB203580 led to a further decrease in Ksp-cadherin
expression. The combination of TβRI inhibitor SB431542
plus p38 MAPK inhibitor SB203580 was not effective in
increasing the Ksp-cadherin RNA level, but addition of
TβRI inhibitor SB431542 together with ROCK inhibitor
Y27632 led to a much greater increase in the Ksp-cadherin
RNA level than the level achieved with either inhibitor by
itself (Figure 4A). TβRI inhibitor SB431542 efficiently
reduced SM22 and MMP-9 expression to pre-EMT levels
(Figures 4B and 4C). The p38 MAPK inhibitor SB203580
did not reduce either the SM22 or MMP-9 expression
level, indicating that presence of this p38 MAPK inhibitor
failed to reverse expression of these genes associated with
the mesenchymal state. The ROCK inhibitor Y27632 par-
tially reduced SM22 expression (Figure 4B), but increased
MMP-9 expression (Figure 4C). This increase in MMP-9
expression was prevented by treatment with TβRI inhibi-
tor SB431542 combined with ROCK inhibitor Y27632
(Figure 4C). Thus, we conclude that the TβRI inhibitor
SB431542 by itself is sufficient to induce the accumula-
tion of some transcripts specific to epithelial cells; how-
ever, the combination of TβRI and ROCK inhibitors can
effectively induce the accumulation of certain additional
epithelial-specific transcripts such as Ksp-cadherin that
correlate with the full reversal of EMT.
One important criterion for epithelium restoration is re-
expression of the cell-cell junction adhesion protein E-
cadherin. To test for this factor, we incubated mTEC-KO
cells with 100 pM TGF-β1 for 72 hours to induce EMT,
added the indicated kinase inhibitors, and continued
incubation for an additional 24 - 48 hours (Figure 5).
Addition of the TβRI inhibitor SB431542 (Figure 5C),
ROCK inhibitor Y27632 (Figure 5D), or p38 MAPK inhib-
itor SB203580 (Figure 5E) by itself led to partial reforma-
tion of E-cadherin at cell junctions compared to the TGF-
β1-treated-mTEC-KOs (Figure 5B). Addition of the TβRI
inhibitor SB431542 together with either p38 MAPK inhib-
itor SB203580 (Figure 5G) or ROCK inhibitor Y27632
(Figure 5H) restored E-cadherin localization to a level
indistinguishable from that observed in the non-TGF-β1-
treated cells (Figure 5A). JNK inhibitor SP600125 alone
(Figure 5F) or a combination of TβRI inhibitor SB431542
plus JNK inhibitor SP600125 (Figure 5I) did not restore
either the level or localization of E-cadherin. The combi-
nation of TβRI inhibitor SB431542 plus ROCK inhibitor
Y27632 was most effective in restoring both localization
of E-cadherin and its protein level as determined by
immunoblot analysis of cell lysates (Figure 5J). Thus, we
conclude that the TβRI, p38 MAPK, and ROCK inhibitors
increase E-cadherin levels; however, the combination of
the TβRI inhibitor with p38 MAPK or ROCK inhibitor is
most effective.
Reduction in ZEB1 levels is necessary for EMT reversal by 
TβRI inhibitor
In the next series of experiments, we decided to examine
the effects of ZEB1 and ZEB2 levels because their expres-
sion is regulated by TGF-β [13] (Additional File 3) and
they are highly expressed in fetal kidney cells [49]. ZEB1
and ZEB2 can also play an important role in EMT induc-
tion by repressing E-cadherin expression [13,15,50-57].
Our data presented above led us to hypothesize that
decreasing expression of transcriptional EMT regulators
such as ZEB1 and ZEB2 is not sufficient for complete EMT
reversal; rather, the presence of a ROCK inhibitor is also
necessary to decrease mesenchymal structural compo-
nents such as stress fibers. Historically, the effects of ZEB1
and ZEB2 have been studied in non-proximal tubule kid-
ney cell lines such as Maderin Darby Canine Kidney
(MDCK) cells [56,58]. We chose here to use Namru
Murine Mammary gland (NMuMG) cells, a traditional
EMT cell culture model [59], because: (i) NMuMG cells
are easier to manipulate than mTEC-KO cells; (ii) they
contain a readily detectable level of ZEB1 protein (Figure
Treatment with a TRβI inhibitor reverses PAI-1 RNA level in  TGF-β1-induced mesenchymal renal tubular epithelial cells to  levels present in epithelial cells Figure 2
Treatment with a TRβI inhibitor reverses PAI-1 RNA 
level in TGF-β1-induced mesenchymal renal tubular 
epithelial cells to levels present in epithelial cells. 
mTEC-KOs were incubated with 100 pM TGF-β1 ligand for 
72 hours, followed by the addition of 5 μM SB431542 plus 
100 pM TGF-β1 for 24 hours. Cell lysates were prepared and 
relative PAI-1 RNA levels were determined by quantitative 
RT-PCR. Significant differences are indicated with an asterisk 
(*) (P <0.05, n = 9).BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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Treatment of mTEC-KO cells with a TβRI inhibitor and a ROCK inhibitor together, but not individually, reverses the mesen- chymal actin cytoskeleton stress fibers induced by TGF-β1 Figure 3
Treatment of mTEC-KO cells with a TβRI inhibitor and a ROCK inhibitor together, but not individually, 
reverses the mesenchymal actin cytoskeleton stress fibers induced by TGF-β1. mTEC-KO cells were incubated 
with 100 pM TGF-β1 for 72 hours, kinase inhibitors were added, and incubation was continued for an additional 24 hours. F-
actin was visualized by staining with Texas Red-phalloidin. mTEC-KO cells were (A) untreated or treated with (B) 100 pM 
TGF-β1 for 72 hours followed by (C-G) single kinase inhibitor or (H-K) SB431542 plus a second kinase inhibitor. Single kinase 
inhibitors and concentrations were as follows: (C) 5 μM SB431542, (D) 1 μM SB203580, (E) 1 μM Y27632, (F) 10 μM U0126, 
and (G) 15 μM SP600125. Combinations of kinase inhibitors were 5 μM SB431542 with (H) 1 μM SB203580, (I) 1 μM 
Y27632, (J) 10 μM U0126, or (K) 15 μM SP600125. (L) Combination of 5 μM Y27632 and 5 μM SB203580. White arrows 
point to stress fibers.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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6); (iii) we could only assay expression of ZEB1 and ZEB2
in mTEC-KO cells by quantitative RT-PCR (Additional File
3), not immunoblotting (data not shown); and (iv) RNA
levels do not necessarily well reflect the protein levels of
ZEB1 and ZEB2 ([60] A.L. Ellis & J.E. Mertz unpublished
data) since ZEB1 and ZEB2 are highly regulated post-tran-
scriptionally [55,56].
NMuMG cells were incubated with 100 pM TGF-β1 for 48
hours to induce EMT, the indicated kinase inhibitors were
added, and incubation was continued for an additional
24 hours (Figure 6). Treatment of NMuMG cells with TGF-
β1 led to a small increase in the level of ZEB1 protein (Fig-
ure 6, lane 2). Following incubation with TβRI inhibitor
SB431542, the level of ZEB1 protein decreased back down
to the level of untreated NMuMG cells (Figure 6, lane 3).
Restoration of epithelial gene expression patterns requires a combination of kinase inhibitors Figure 4
Restoration of epithelial gene expression patterns requires a combination of kinase inhibitors. mTEC-KO cells 
were incubated with 100 pM TGF-β1 for 72 hours to induce EMT. Afterward, they were incubated for an additional 24 hours 
with the indicated individual or combination of kinase inhibitors: 5 μM SB431542, 1 μM SB203580, and 1 μM Y27632. (A) Ksp-
cadherin, (B) SM22, and (C) MMP-9 mRNA levels were determined by quantitative RT-PCR. Significant differences between 
the untreated cells (lane 1) versus cells treated with TGF-β1 (lane 2) or TGF-β1 followed by inhibitors (lanes 3-7) are indi-
cated by asterisks (*) (P < 0.05, n = 9).BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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E-cadherin expression is restored by combined treatment with a TβRI kinase inhibitor and either a ROCK or p38 MAPK inhib- itor Figure 5
E-cadherin expression is restored by combined treatment with a TβRI kinase inhibitor and either a ROCK or 
p38 MAPK inhibitor. A-I Phase contrast microscopy of mTEC-KO cells incubated for 72 hours with 100 pM TGF-β1 fol-
lowed by the indicated inhibitor(s) for an additional 36 hours prior to fixing and staining with DAPI. (A) untreated control 
cells; (B) treated only with TGF-β1; treated individually with the inhibitors (C) 5 μM SB431542, (D) 5 μM SB203580, (E) 5 
μM Y27632, or (F) 15 μM SP600125; and treated together with 5 μM SB431542 plus (G) 5 μM SB203580, (H) 5 μM Y27632, 
or (I) 15 μM SP600125. (J) Immunoblot analysis of cell lysates obtained from the above-treated mTEC-KOs for the presence 
of E-cadherin. β-tubulin served as a control.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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Incubation with ROCK inhibitor Y27632 by itself led to a
significant increase in the level of ZEB1 (Figure 6, lane 4);
however, if cells treated with the ROCK inhibitor Y27632
were also incubated with TβRI inhibitor SB431542 (Fig-
ure 6, lane 6), the level of ZEB1 decreased to the level of
untreated cells. ZEB2 protein was difficult to detect with
our antibody; nevertheless, we could readily detect ZEB2
protein in the cells incubated with TβRI inhibitor
SB431542 plus JNK inhibitor SP600125 (Figure 6, lane
5), indicating this combination of inhibitors led to
increased expression of ZEB2 even if not ZEB1. From these
results, we conclude that incubation with TβRI inhibitor
can reverse the increase in ZEB1 levels.
We next tested whether the decrease in ZEB1 level by
kinase inhibitors restored E-cadherin expression in
NMuMG cells treated with TGF-β. Similar to our findings
in the mTEC-KO model system, incubation with TGF-β1
led to loss of E-cadherin (Figure 6, lane 2). Incubation
with either the TβRI inhibitor SB431542 (Figure 6, lane 3)
or the TβRI inhibitor SB431542 in combination with
ROCK inhibitor Y27632 (Figure 6, lane 6) restored the E-
cadherin level. ROCK inhibitor Y27632 alone was not
effective in restoring the E-cadherin level (Figure 6, lane
4). E-cadherin was also not restored in cells incubated
with TβRI inhibitor SB431542 plus JNK inhibitor
SP600125 (Figure 6, lane 5). Although the ZEB1 level was
similar to the cells incubated with the TβRI inhibitor
SB431542 and ROCK inhibitor Y27632 (Figure 6, lane 6),
the cells incubated with TβRI inhibitor SB431542 plus
JNK inhibitor SP600125 also expressed ZEB2 (Figure 6,
lane 5) which could account for the observed repression
of E-cadherin expression. These data indicate that inhibi-
tion of the TGF-β-induced increase in ZEB1 levels can lead
to re-expression of E-cadherin. However, the re-expression
of E-cadherin can be inhibited if ZEB2 is expressed.
Restoration of E-cadherin expression in NMuMG cells is dependent on levels of ZEB1 and ZEB2 Figure 6
Restoration of E-cadherin expression in NMuMG cells is dependent on levels of ZEB1 and ZEB2. NMuMG cells 
were incubated for 48 hours with 100 pM TGF-β1 to induce EMT. Thereafter, the cells were incubated for an additional 24 
hours with the indicated inhibitors: (lane 3), 1 μM SB431542; (lane 4), 1 μM Y27632; (lane 5), 1 μM SB431542 and 10 μM 
SP600125; and (lane 6), 1 μM SB431542 and 1 μM Y27632. NMuMG cells were also infected with shRNAmir-targeting ZEB1 
and ZEB2 lentiviruses followed by incubation for an additional 24 hours without TGF-β1 (lane 7), with 100 pM TGF-β1 (lane 
8), or with 100 pM TGF-β1 plus 1 μM Y27632 (lane 9). Levels of ZEB1, ZEB2, E-cadherin, and β-actin protein in the cells 
were assessed by immunoblot analysis. Dash indicates protein present at level below background; plus sign indicates protein 
present at clearly detectable level. Similar findings were observed in two other independent experiments.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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To test whether ZEB1 and ZEB2 levels directly affect E-cad-
herin expression, we performed RNA-mediated interfer-
ence experiments. NMuMG cells infected with lentiviruses
expressing a pool of individual ZEB1 and ZEB2 shRNAs
knocked down endogenous expression of ZEB1 to a
nearly undetectable level within 72 hours regardless of
whether the cells had been treated with TGF-β1 (Figure 6,
lanes 7-9). Although ZEB2 protein was not detected by
our assay in these cells, we included shRNAs targeting
ZEB2 because others reported detection of ZEB2 RNA in
TGF-β1 treated NMuMg cells [13]. While incubation with
TGF-β1 led to loss of E-cadherin (Figure 6, lane 2), this
treatment with ZEB1 plus ZEB2 shRNAs restored E-cad-
herin to levels that were higher as compared to the origi-
nal cells (Figure 6, lane 8). ZEB depletion together with
incubation with 1 μM Y27632 also led to increased E-cad-
herin expression (Figure 6, lane 9). Thus, we conclude that
depletion of ZEB by either shRNAs or kinase inhibitors is
sufficient to re-introduce E-cadherin expression in TGF-β-
induced mesenchymal cells.
ZEB1 depletion combined with ROCK inhibitor Y27632 is 
required to complete the EMT reversal program by 
eliminating stress fibers
Loss of E-cadherin is accompanied by rearrangement of
the actin cytoskeleton to maintain polarized cell structure.
NMuMG cells treated with TGF-β exhibit stress fibers and
lower cell number (Figure 7B). Thus, we also examined
the effect of ZEB level on the arrangement of F-actin stress
fibers in NMuMG cells. Treatment of the cells with shR-
NAs against ZEB1 and ZEB2 led to attenuation of the
stress fibers (Figure 7C); however, the arrangement of F-
actin did not completely reverse as compared to the cells
incubated with the kinase inhibitors (Figure 3). On the
other hand, NMuMG cells treated with TGF-β and incu-
bated with ROCK inhibitor Y27632 together with the ZEB
shRNAs exhibited decreased F-actin fibers and reappear-
ance of cortical actin (Figure 7D). This failed to occur
when TGF-β-treated cells infected with the viruses express-
ing the shRNAs against the ZEBs were incubated with JNK
inhibitor SP600125 (Figure 7E). Taken together, these
data indicate that ROCK inhibitor Y27632 treatment leads
to stabilization of cortical actin, while reduction in expres-
sion of the ZEBs leads to increased expression of factors
such as E-cadherin necessary for EMT reversal.
Discussion
The goal of this study was to elucidate molecular mecha-
nisms involved in maintaining the mesenchymal state
induced by TGF-β1. Here, we demonstrated that prevent-
ing EMT requires blocking the TβRI kinase (Figure 1),
while reversing the EMT program is more complex, requir-
ing inhibition of both TβRI kinase and ROCK (Figures 3,
4, 5, 6). A p38 MAPK inhibitor also plays a role by work-
ing in conjunction with the TβRI kinase inhibitor to fur-
ther lessen the mesenchymal structural elements to
reverse EMT (Figure 3). We defined the success of an agent
in reversing EMT as the re-expression of key epithelial pro-
teins (e.g., E-cadherin, cortical actin) and the re-position-
ing of these proteins to allow for epithelial cell
morphology. We also demonstrated that reversal of EMT
by the TβRI inhibitor SB431542 involves, in part, inhibit-
ing expression of ZEB1, a key transcriptional repressor of
E-cadherin expression and the epithelial state (Figure 6).
Taken together, these findings indicate that TGF-β main-
tains the mesenchymal phenotype through sustained acti-
vation of Smad-dependent transcriptional responses and
elements downstream from ROCK (Figure 8).
Decreasing ZEB1 and ZEB2 expression enables partial re-
programming of EMT by inducing E-cadherin expression
The levels of ZEB1 and ZEB2 can regulate the epithelial
transition to the mesenchymal state, [51-56,60,61]. In
Madin-Darby Canine Kidney (MDCK) cells, EMT is pre-
ceded by the loss of mature miR200a-c, inducing up-regu-
lation of ZEB1 and ZEB2 expression followed by loss of E-
cadherin expression and transition to the mesenchymal
state [50,59,62,63]. In cancers or fibrosis, this feedback
loop may be disrupted, leading to unregulated expression
of ZEB1 or ZEB2. To regain this feedback loop, a small
molecule inhibitor of TβRI may be useful to block factors
maintaining the mesenchymal state. In this case, blocking
the feedback loop during TGF-β1-induced maintenance of
ZEB1 levels might enable re-expression of miRNA200
family members and proteins involved in epithelial cell
morphology (Figure 8).
Thuault et al. [33] previously examined the role of Snail,
another E-box-binding transcriptional repressor of E-cad-
herin gene expression, in EMT reversal. They reported that
High Mobility Group A2 (HMGA2) sustains TGF-β-
induced EMT in NMuMG cells, with partial EMT reversal
occurring as measured by restoration of tight junction
proteins and a partial restoration of cortical actin when
Snail is targeted for depletion by shRNA. However, E-cad-
herin did not re-colocalize or become expressed at cell-cell
junctions, indicating that either Snail was not sufficiently
knocked down in their experiment or there was another
factor regulating localization of the cytoskeleton compo-
nents.
Our studies demonstrate that depleting mesenchymal
cells of ZEB1 and ZEB2 with specific shRNAs or using a
TRβI inhibitor in combination with a ROCK inhibitor is
sufficient to restore fully E-cadherin protein levels (Fig-
ures 6 and 7). However, solely targeting ZEB1 and ZEB2
with shRNAs did not lead to full restoration of cortical
actin at the cell borders; rather, treatment as well with a
ROCK inhibitor was necessary for complete reduction ofBMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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ZEB1 and ZEB2 depletion by shRNAs in NMuMG cells attenuates F-actin stress fibers Figure 7
ZEB1 and ZEB2 depletion by shRNAs in NMuMG cells attenuates F-actin stress fibers. Cells were treated as indi-
cated with 100 pM TGF-β1 for 48 hours followed by an additional 72 hour incubation with a lentivirus encoding pLKO.1 (a 
control shRNA) or lentiviruses encoding shRNAs against ZEB1 and ZEB2, with 1 μM Y27632 or 10 μM SP600125 added during 
the last 24 hour incubation with the shRNAs. F-actin was visualized by phalloidin. Cells were viewed at a 400× magnification. 
White arrows point to stress fibers.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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stress fibers (Figure 7). Other factors may also be neces-
sary to maintain the epithelial cytoskeleton.
ROCK regulates the cytoskeleton during EMT reversal to 
stabilize the epithelial structure
One plausible regulator of the actin cytoskeleton is Rho.
Here, we showed that ROCK is responsible for only a sub-
set of EMT changes, such as actin rearrangement (Figures
3 and 7). Inhibiting ROCK was not sufficient to induce E-
cadherin or other epithelial characteristics (Figures 3, 4, 5,
6). This finding implies that ROCK is necessary for epithe-
lial cells to regain cytoskeletal structure. We hypothesize
that re-acquisition of the epithelial cytoskeleton might
sequester the mesenchymal signaling associated with the
unformed cell-cell adhesions [64]. In mammary gland
epithelial cells, Rho location is controlled by the parti-
tioning-defective protein 6C (Par6), a regulator of the
polarity complex [8]. When TβRII is activated, Par6 is
phosphorylated and recruits the E3 ubiquitin ligase
Smurf1 to the cell membrane, thereby regulating the
localization of Rho by ubiquitination. This implies that
the location of Rho is important for the arrangement of
actin in epithelial cells. To determine the mechanism of
TGF-β activation of stress fibers, further studies are needed
to examine if TGF-β induces F-actin stress fibers as the
result of ROCK activating LIM kinase and cofilin [65,66]
or by ROCK regulating gene expression through Jak-Stat
and NF-B pathways [67].
Model for reversal of EMT induced by TGF-β1 Figure 8
Model for reversal of EMT induced by TGF-β1. To re-express epithelial proteins such as E-cadherin, a TβRI kinase inhib-
itor is needed to decrease expression of mesenchymal genes (e.g., ZEB1 and ZEB2), while a Rho kinase inhibitor is required to 
stabilize the epithelial cortical actin. A p38 MAPK inhibitor may also be useful as this drug in conjunction with the TβRI kinase 
inhibitor can further EMT reversal by reducing stress fiber actin formation.BMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
Page 13 of 18
(page number not for citation purposes)
Temporal control of EMT reversal varies with the agents 
and cell type
Other reports of mesenchymal phenotypic reversion uti-
lizing inhibitors have claimed various degrees of success.
For example, EMT induced in EpH4 mouse mammary epi-
thelial cells by an estradiol-inducible c-Fos-estrogen
receptor fusion protein was only partially reversed after 3
- 6 days of incubation with BIBU 3029, a small molecule
inhibitor of TβRI kinase [68]. However, ectopic expression
of E-cadherin combined with addition of BIBU 3029 did
lead to full reversal of the EpH4 mesenchymal cells as
assayed by the formation of cobblestone-like epithelial
sheets with tight junctions between the cells and localized
expression of E-cadherin and β-catenin at cell junctions,
but only after 6 days. Others have reported that incuba-
tion with individual inhibitors of TβRI kinase is sufficient
to increase E-cadherin expression and to induce a more
epithelial morphological appearance within 48 hours in
several cell lines [69-71]. By contrast, our study showed
that a combination of a TβRI inhibitor and a ROCK inhib-
itor can enable complete, rapid reversal of EMT within 24
hours, including re-expression of Ksp-cadherin and E-cad-
herin (Figures 4 and 5). Plausible explanations for the dif-
ferences in our observations include (i) the agents
employed to induce EMT, and (ii) the specific cell types
used in the experiments.
Chemical inhibition of JNK blocks EMT reversal by the 
TβRI inhibitor
Our studies demonstrate that small molecule inhibition
of JNK can block the reversal effects of the TβRI inhibitor
by maintaining stress fibers and decreasing E-cadherin
levels (Figures 3, 5, 6, 7). Suppression of JNK leads to
increased expression of the transcription factor Slug in tro-
phoblast stem cells, leading to induction of an EMT state
[72]. Like ZEB1 and ZEB2, Slug induces EMT by repressing
expression of E-cadherin via binding to E-box elements in
the E-cadherin promoter [73]. Another plausible explana-
tion for maintenance of non-TGF-β-dependent EMT is
that the JNK inhibitor may activate other pathways such as
NF-B [29]. Previous studies demonstrated NF-B both sup-
presses apoptosis and induces EMT in breast cancer cells
[74]. NF-B has been shown to induce EMT by upregulat-
ing E-cadherin transcriptional repressors such as Snail,
Slug, ZEB1, and ZEB2 [29]. This indicates that a JNK
inhibitor should not be used in conjunction with a TβRI
inhibitor as doing so may compromise EMT reversal.
Inhibitors in combination may be a feasible therapeutic 
approach for treating patients with EMT-associated 
diseases
In chronic fibrotic diseases, reversal of the mesenchymal
state generated by EMT may be critical for restoring func-
tion to organs. For example, it might provide a potential
therapy for treating chronic kidney damage caused by
constitutively high levels of TGF-β1 [3]. Blocking EMT is
useful for preventative medicine. However, reversing EMT
holds more promise for treating existing diseases. Our use
of small molecule inhibitors of individual protein kinases
not only demonstrates their potential for dissecting mech-
anisms of signal transduction for specific ligands and for
delineating their roles in biologic responses, but also their
potential as therapeutic agents. Yingling et al. have
described a group of competitive ATP-binding site inhibi-
tors of ALK-5 as possible agents for treating some cancers
and fibrosis [75]. In certain cancers, treatment with a TβRI
inhibitor shows promise in halting metastasis [33,68-
70,76,77]. Therapeutics in the form of growth factors such
as BMP-7 can also act as TGF-β antagonists to treat fibrotic
disease [78]. Other approaches to block TGF-β activity,
such as anti-sense DNA targeting TGF-β, are in clinical tri-
als as a vaccine against tumor cells or as therapeutics for
treating patients with high-grade gliomas [79,80]. In addi-
tion, ROCK and p38 MAPK inhibitors are in clinical trials
as potential therapeutics targeting a variety of cancers
[81,82]. These recent developments suggest multiple ther-
apeutic strategies may be possible for treating patients
with diseases in which TGF-β-induced EMT contributes to
the pathology.
Conclusion
We showed here that reversing EMT in mTEC-KO cells
requires inhibition of both TβRI kinase and ROCK. The
TβRI kinase inhibitor decreased expression of ZEB1 and
ZEB2, thereby increasing expression of the epithelial pro-
tein E-cadherin, and the ROCK inhibitor was necessary to
fully eliminate mesenchymal actin stress fibers (Figure 8).
Methods
Cells and Reagents
Early passage (passage 2) TGF-β1 knockout murine renal
tubular epithelial cells (mTEC-KO) and early passage
(passage 5) murine renal tubular epithelial cells (mTEC-
WT) were generously provided to us by Dr. Jeffrey Kopp
(National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD). The cells were grown until pas-
sage 20. They were maintained in Renal Epithelial Cell
Growth Medium (Cambrex, MD) supplemented with
0.25% fetal bovine serum (FBS), a Bullet Kit that con-
tained epidermal growth factor, insulin, hydrocortisone,
GA-1000, epinephrine, T3, and transferrin (Cambrex, NJ),
and penicillin and streptomycin (Gibco-Invitrogen, CA).
Namru murine mammary gland (NMuMG) cells were
obtained from Dr. Caroline Alexander (UW-Madison,
WI). They were grown in DMEM supplemented with 10%
FBS, 10 μg/ml insulin, 100 μg/ml penicillin, and 100 U/
ml streptomycin. 293T cells were purchased from ATCC
(VA). They were grown in 10% DMEM supplemented
with 10% FBS, 100 μg/ml penicillin, and 100 U/ml strep-
tomycin. All cells were maintained in a 37°C humidifiedBMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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5% CO2  incubator. Carrier-free TGF-β1 was obtained
from R&D Systems (MN). Chemical inhibitors SB203580,
SP600125, and Y27632 (Calbiochem, CA); SB431542
(Sigma, MO); and U0126 (Promega, WI) were aliquoted
after reconstitution and frozen at -80°C.
Production of Lentiviruses
The lentiviral shRNAmir vectors targeting ZEB1 (target set
NM_011546), ZEB2 (target set NM_014795), and control
pLKO.1 (RHS4080) were purchased from OpenBiosys-
tems (Thermo Scientific, AL). Plasmid pLKO.1 contains a
scrambled sequence that results in synthesis of a shRNA
that does not appear to inhibit expression of any known
cellular gene. To generate virus, mycoplasma-free 293T
cells were transfected using LT1 (Mirus, WI) with 10 μg
total of a mixture containing shRNAmir ZEB1 and ZEB2
or pLKO.1 as indicated, 3 μg lentiviral DNA encoding
Gag/Pol, and 1 μg VSVG [83] (provided by Dr. Bill Sug-
den, Madison, WI). The medium was supplemented with
50 mM HEPES solution, pH 7.3 (Invitrogen) and changed
after 6 hours. Viral supernatant was collected after 24
hours and passed through a 0.45 μm filter. NMuMG cells
were infected daily with the pool of shZEB1 and shZEB2
viruses over 48 - 72 hours to decrease ZEB1 and ZEB2
expression.
Immunoblotting
After treatment as indicated, cells were washed with cold
PBS, lyzed in TNE buffer [50 mM Tris-HCl (pH 8.0), 1%
NP40, 150 mM NaCl, 5 mM EDTA] and pelleted by cen-
trifugation at 14,000 rpm for 5 min at 4°C. Lysates were
prepared using TNE buffer supplemented with protease
inhibitor cocktail (Roche, NJ) and protease inhibitor
cocktail solution III (Calbiochem, CA). Cell homogenates
were incubated for 10 min at 100°C in 2× loading buffer.
Equal amounts of protein, as assessed by BCA Protein
Assay Kit (BioRad, CA), were added to each well. The pro-
teins were separated by electrophoresis in 4% - 20% gra-
dient polyacrylamide gels (ISC BioExpress, UT) and
transferred to PVDF membranes (Millipore, MA) or nitro-
cellulose filters (ISC Biosystem, UT). The primary anti-
bodies used for detection were as follows: E-cadherin (BD
Biosciences, CA), ZEB1 (H102, Santa Cruz Biotechnology,
CA), ZEB2 (Dr. Michel Sanders, University of Minnesota,
MN; purified by Dr. Xianming Yu, UW-Madison, WI), and
α-Smooth Muscle Actin (Sigma). Anti-mouse IgG conju-
gated with horseradish peroxidase (Millipore) was used as
the secondary antibody. Blots were developed by ECL (GE
Healthcare, NJ). Where indicated, the immunoblots were
stripped by incubation with 100 mM β-mercaptoethanol,
2% SDS, 62.5 mM TRIS (pH 8.2) at 65°C for 1 hour and
reprobed with β-actin (Sigma) or β-tubulin (Sigma) pri-
mary antibody as indicated and HRP secondary antibody
(GE Healthcare). Relative protein levels were determined
by densitometry using Bio-Rad Quantity One Software
(Bio-Rad), with normalization to the amount of cellular
β-actin or β-tubulin present in each sample. Changes in
the amount of a protein present in an experimental sam-
ple are shown relative to the amount of this protein
present in the untreated control sample processed in par-
allel.
Quantitative RT-PCR
After treatment as indicated, total RNA was isolated from
the cells using RNAeasy Miniprep kit (Qiagen) and quan-
tified by UV spectrophotometer. 1.5 μg of RNA from each
sample was converted by reverse transcriptase into cDNA
using an OmniScript kit (Qiagen). Primers used for qRT-
PCR were as follows: mouse Ksp-cadherin: forward-5'-
CTGCACACAGAAGTCCCTGA-3', reverse 5'-CCTT-
GTCGCCACTAGAAAGC-3'; mouse MMP-9: SuperArray
primer (MD) PPM03661A; mouse SM22: forward 5'-
GCAGTCCAAAATTGAGAAGA-3', reverse 5'-
CTGTTGCTGCCCATTTGAAG3'; mouse PAI-1: forward 5'-
TTCAGCCCTTGCTTGCCTC-3', reverse 5'-ACACTTT-
TACTCCGAAGTCGGT-3'; ZEB1: forward 5'-AACGGA-
GATTTGTCTCCCAGT-3', reverse 5'-
CTGTCCAGCTTGCATCTTTTC-3'; ZEB2: forward 5'-
TAGCCGGTCCAGAAGAAATG-3', reverse 5'-
GGCCATCTCTTTCCTCCAGT-3'[20]; mouse GAPDH: for-
ward 5'-AGGTCGGTGTGAACGGATTTG-3', reverse 5'-
TGTAGACCATGTAGTTGAGGTCA-3'; and P0: forward, 5'-
GACAATGGCAGCATCTACAAC-3', reverse, 5'-GCA-
GACAGACACTGGCAAC-3' [84]. cDNA was amplified in
an Opticon 2 PCR machine (MJ Research) and labelled
using an ABI SYBR Green qPCR Kit (ABI Systems, CA). The
amplifications were carried out in the following manner:
initial denaturation for 10 min at 95C, denaturation for
10 sec at 95°C, annealing for 30 sec at an optimal temper-
ature for each cDNA, and extension for 30 sec at 72°C.
Standards were created from Pfu (Stratagene, CA)-ampli-
fied PCR products purified by gel electrophoresis. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control to normalize gene expression
levels, except for ZEB1 and ZEB2 where the ribosomal
protein P0 was used, instead. Relative ZEB1 and ZEB2
RNA levels were calculated by a modified Ct method [85].
Immunofluorescence
Cells were seeded on glass cover slips (Fisher, PA) or 8-
well chamber slides (Fisher) and cultured as described.
Afterward, the cells were fixed by incubation in 4% para-
formaldehyde for 5 min and permeabilized in PBS con-
taining 0.1% Triton X-100 for 10 min. Non-specific
binding was blocked with 10% BSA or normal goat serum
for 30 min. F-actin was stained at a 1:1000 dilution in 2%
BSA of Texas Red-conjugated or FITC-conjugated phalloi-
din (Sigma) for at least 30 min. E-cadherin (BD Bio-
sciences) was diluted 1:50 in 2% normal goat serum and
incubated overnight. A secondary antibody made in goatBMC Cell Biology 2009, 10:94 http://www.biomedcentral.com/1471-2121/10/94
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(Invitrogen) was used at a 1:1000 dilution and incubated
for 2 hours in a humid chamber with minimal exposure
to light. All washes were done in 1× PBS. An anti-fade
solution containing DAPI (Vector Laboratories, CA) was
used in mounting the slides. Images were taken at room
temperature with an Axiocam digital camera attached to a
Zeiss microscope. Axiovision was used to acquire the
image. Adobe Photoshop was used to merge images.
Statistical Analysis
Unless indicated otherwise, all experiments were per-
formed on three separate occasions, each time with tripli-
cates, with the figures showing means of the triplicates for
one of the experiments (n = 3). For statistical evaluation,
the data from all experimental replicates were pooled (n =
9). For comparisons between pairs, we used one-way anal-
ysis of Wilcoxson Rank Sums determined with MSTAT
software http://mcardle.oncology.wisc.edu/mstat. A p
value < 0.05 was considered statistically significant.
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